Inari Medical Inc (NARI)

$65.4

-1.28

(-1.92%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Inari Medical Inc

  • Increasing Revenue

    Revenue is up for the last 13 quarters, 25.39M → 119.00M (in $), with an average increase of 11.6% per quarter

  • Increasing Revenue

    Revenue is up for the last 13 quarters, 25.39M → 119.00M (in $), with an average increase of 11.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -10.18M → 2.08M (in $), with an average increase of 110.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -10.18M → 2.08M (in $), with an average increase of 110.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 36.3% return, outperforming this stock by 46.3%

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 36.3% return, outperforming this stock by 46.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 37.4% return, outperforming this stock by 40.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 37.4% return, outperforming this stock by 40.8%

Performance

  • $65.31
    $67.25
    $65.40
    downward going graph

    0.14%

    Downside

    Day's Volatility :2.88%

    Upside

    2.75%

    downward going graph
  • $52.59
    $83.84
    $65.40
    downward going graph

    19.59%

    Downside

    52 Weeks Volatility :37.27%

    Upside

    21.99%

    downward going graph

Returns

PeriodInari Medical IncSector (Health Care)Index (Russel 2000)
3 Months
15.36%
-3.0%
0.0%
6 Months
8.12%
-0.6%
-1.9%
1 Year
-12.36%
6.3%
6.3%
3 Years
-3.41%
22.5%
15.5%

Highlights

Market Capitalization
3.8B
Book Value
$7.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.29
Wall Street Target Price
85.7
Profit Margin
-3.66%
Operating Margin TTM
-5.13%
Return On Assets TTM
-2.79%
Return On Equity TTM
-3.79%
Revenue TTM
439.1M
Revenue Per Share TTM
8.01
Quarterly Revenue Growth YOY
28.299999999999997%
Gross Profit TTM
339.0M
EBITDA
-17.4M
Diluted Eps TTM
-0.29
Quarterly Earnings Growth YOY
-0.84
EPS Estimate Current Year
0.06
EPS Estimate Next Year
0.36
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Inari Medical Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 31.04%

Current $65.40
Target $85.70

Company Financials

FY18Y/Y Change
Revenue
6.8M
-
Net Income
-10.2M
-
Net Profit Margin
-148.67%
-
FY19Y/Y Change
Revenue
51.1M
↑ 648.7%
Net Income
-1.2M
↓ 88.26%
Net Profit Margin
-2.33%
↑ 146.34%
FY20Y/Y Change
Revenue
139.7M
↑ 173.17%
Net Income
13.8M
↓ 1256.97%
Net Profit Margin
9.87%
↑ 12.2%
FY21Y/Y Change
Revenue
277.0M
↑ 98.31%
Net Income
9.8M
↓ 28.64%
Net Profit Margin
3.55%
↓ 6.32%
FY22Y/Y Change
Revenue
383.5M
↑ 38.45%
Net Income
-29.3M
↓ 397.43%
Net Profit Margin
-7.63%
↓ 11.18%
Q1 FY22Q/Q Change
Revenue
86.8M
↑ 4.25%
Net Income
-3.1M
↓ 382.66%
Net Profit Margin
-3.61%
↓ 4.94%
Q2 FY22Q/Q Change
Revenue
92.7M
↑ 6.91%
Net Income
-10.2M
↑ 225.57%
Net Profit Margin
-10.98%
↓ 7.37%
Q3 FY22Q/Q Change
Revenue
96.2M
↑ 3.73%
Net Income
-10.2M
↓ 0.33%
Net Profit Margin
-10.55%
↑ 0.43%
Q4 FY22Q/Q Change
Revenue
107.8M
↑ 12.02%
Net Income
-5.8M
↓ 42.89%
Net Profit Margin
-5.38%
↑ 5.17%
Q1 FY23Q/Q Change
Revenue
116.2M
↑ 7.79%
Net Income
-2.2M
↓ 61.75%
Net Profit Margin
-1.91%
↑ 3.47%
Q2 FY23Q/Q Change
Revenue
119.0M
↑ 2.44%
Net Income
2.1M
↓ 194.0%
Net Profit Margin
1.75%
↑ 3.66%
FY18Y/Y Change
Total Assets
26.9M
-
Total Liabilities
66.3M
-
FY19Y/Y Change
Total Assets
44.5M
↑ 65.59%
Total Liabilities
83.7M
↑ 26.14%
FY20Y/Y Change
Total Assets
214.1M
↑ 380.6%
Total Liabilities
13.8M
↓ 83.47%
FY21Y/Y Change
Total Assets
311.5M
↑ 45.52%
Total Liabilities
72.3M
↑ 422.71%
FY22Y/Y Change
Total Assets
504.2M
↑ 61.82%
Total Liabilities
87.2M
↑ 20.48%
Q1 FY22Q/Q Change
Total Assets
484.1M
↑ 55.39%
Total Liabilities
65.3M
↓ 9.73%
Q2 FY22Q/Q Change
Total Assets
484.3M
↑ 0.03%
Total Liabilities
70.5M
↑ 7.94%
Q3 FY22Q/Q Change
Total Assets
487.8M
↑ 0.73%
Total Liabilities
72.7M
↑ 3.17%
Q4 FY22Q/Q Change
Total Assets
504.2M
↑ 3.35%
Total Liabilities
87.2M
↑ 19.84%
Q1 FY23Q/Q Change
Total Assets
506.5M
↑ 0.47%
Total Liabilities
79.8M
↓ 8.44%
Q2 FY23Q/Q Change
Total Assets
525.0M
↑ 3.64%
Total Liabilities
89.3M
↑ 11.94%
FY18Y/Y Change
Operating Cash Flow
-10.9M
-
Investing Cash Flow
-753.0K
-
Financing Cash Flow
26.8M
-
FY19Y/Y Change
Operating Cash Flow
-4.9M
↓ 54.68%
Investing Cash Flow
-3.1M
↑ 317.53%
Financing Cash Flow
10.2M
↓ 61.79%
FY20Y/Y Change
Operating Cash Flow
1.9M
↓ 138.74%
Investing Cash Flow
-55.4M
↑ 1663.26%
Financing Cash Flow
144.1M
↑ 1309.64%
FY21Y/Y Change
Operating Cash Flow
25.5M
↑ 1232.95%
Investing Cash Flow
-51.0M
↓ 7.96%
Financing Cash Flow
4.1M
↓ 97.17%
Q1 FY22Q/Q Change
Operating Cash Flow
-9.1M
↓ 160.64%
Investing Cash Flow
-73.5M
↑ 2666.69%
Financing Cash Flow
176.5M
↓ 28574.52%
Q2 FY22Q/Q Change
Operating Cash Flow
-3.1M
↓ 66.36%
Investing Cash Flow
-101.9M
↑ 38.56%
Financing Cash Flow
-1.6M
↓ 100.9%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.1M
↑ 326.85%
Investing Cash Flow
13.4M
↓ 113.16%
Financing Cash Flow
3.9M
↓ 343.26%
Q2 FY23Q/Q Change
Operating Cash Flow
9.8M
↓ 584.85%
Investing Cash Flow
-6.1M
-
Financing Cash Flow
-2.4M
↓ 195.38%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inari Medical Inc
Inari Medical Inc
-1.4%
8.12%
-12.36%
-3.41%
53.85%
Stryker Corporation
Stryker Corporation
-3.93%
-4.97%
30.23%
30.96%
52.96%
Boston Scientific Corp.
Boston Scientific Corp.
-1.53%
6.19%
32.4%
38.18%
35.45%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-9.3%
-15.69%
-16.16%
-13.2%
21.67%
Abbott Laboratories
Abbott Laboratories
-5.83%
-4.67%
-2.68%
-10.85%
30.67%
Medtronic Plc
Medtronic Plc
-4.59%
-1.64%
-2.96%
-24.6%
-21.24%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inari Medical Inc
Inari Medical Inc
NA
NA
NA
0.06
-0.04
-0.03
0.0
7.61
Stryker Corporation
Stryker Corporation
38.6
38.6
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
90.46
90.46
2.53
2.0
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.09
31.09
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
33.49
33.49
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
29.04
29.04
3.04
5.28
0.07
0.04
0.04
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inari Medical Inc
Inari Medical Inc
Buy
$3.8B
53.85%
NA
-3.66%
Stryker Corporation
Stryker Corporation
Buy
$103.8B
52.96%
38.6
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$78.1B
35.45%
90.46
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.5B
21.67%
31.09
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$170.3B
30.67%
33.49
12.83%
Medtronic Plc
Medtronic Plc
Buy
$104.7B
-21.24%
29.04
11.47%

Institutional Holdings

  • BlackRock Inc

    11.13%

  • Wellington Management Company LLP

    9.54%

  • Vanguard Group Inc

    8.28%

  • Franklin Resources Inc

    4.74%

  • AllianceBernstein L.P.

    4.02%

  • State Street Corporation

    3.09%

Corporate Announcements

  • Inari Medical Inc Earnings

    Inari Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.

Organization
Inari Medical Inc
Employees
1100
CEO
Mr. William H. Hoffman
Industry
Health Technology

Discover More

FAQs